Zhai Zhenzhen, Huang Yanxin, Zhang Yawei, Zhao Lili, Li Wen
School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China.
Collaborative Innovation Center of New Drug Research and Safety Evaluation, Henan Province & Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education & Key Laboratory of Henan Province for Drug Quality and Evaluation, Zhengzhou 450001, China.
Antioxidants (Basel). 2022 Aug 12;11(8):1564. doi: 10.3390/antiox11081564.
Studies have found that inflammation is a symptom of various diseases, such as coronavirus disease 2019 (COVID-19) and rheumatoid arthritis (RA); it is also the source of other diseases, such as Alzheimer's disease (AD), Parkinson's disease (PD), lupus erythematosus (LE), and liver damage. Nrf2 (nuclear factor erythroid 2-related factor 2) is an important multifunctional transcription factor in cells and plays a central regulatory role in cellular defense mechanisms. In recent years, several studies have found a strong association between the activation of Nrf2 and the fight against inflammation-related diseases. A number of small molecule compounds targeting Nrf2 have entered clinical research. This article reviews the research status of small molecule compounds that are in clinical trials for the treatment of COVID-19, rheumatoid arthritis, Alzheimer's disease, Parkinson's disease, lupus erythematosus, and liver injury.
研究发现，炎症是多种疾病的症状，如2019冠状病毒病（COVID-19）和类风湿性关节炎（RA）；它也是其他疾病的根源，如阿尔茨海默病（AD）、帕金森病（PD）、红斑狼疮（LE）和肝损伤。Nrf2（核因子红细胞2相关因子2）是细胞中一种重要的多功能转录因子，在细胞防御机制中起核心调节作用。近年来，多项研究发现Nrf2的激活与对抗炎症相关疾病之间存在密切关联。一些靶向Nrf2的小分子化合物已进入临床研究。本文综述了用于治疗COVID-19、类风湿性关节炎、阿尔茨海默病、帕金森病、红斑狼疮和肝损伤的处于临床试验阶段的小分子化合物的研究现状。
